Botox com­peti­tor Daxxi­fy hits $15.4M in Q1 earn­ings as mak­er faces trade se­crets law­suit

The sec­ond round of rev­enue num­bers is in for Daxxi­fy, Re­vance Ther­a­peu­tics’ longer-last­ing cos­met­ic in­jec­tion set to com­pete against Ab­b­Vie’s Botox.

Re­vance Ther­a­peu­tics on Tues­day said the drug, which was ap­proved by FDA in Sep­tem­ber, brought in $15.4 mil­lion in rev­enue in the first quar­ter. Re­vance launched an “ear­ly ex­pe­ri­ence pro­gram” for Daxxi­fy in De­cem­ber, with a broad­er com­mer­cial launch in March.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters